Deutsche Bank Maintains Buy on Sutro Biopharma, Raises Price Target to $55 - Sutro Biopharma (NASDAQ:STRO)
Published on March 25, 2026.
The world's largest bank has maintained its position as a Buy on the stock market. The bank has raised its price target to $55. The article discusses the potential impact of this move on the market.
.
. The financial implications for the company are uncertain.
Related Articles
AI agents to help investigators unearth crypto criminals, according to new TRM program
Trained Institutionalization (TRM) is deploying AI-based agents to speed up investigations into crypto criminals, enhancing the effectiveness of existing investigations into fraud and scams.
Crypto's Biggest Betrayal: 'Senator Lummis Was On Our Team, Now She's Not,' Mark Yusko Says
Venture capitalist Mark Yusko criticizes Senator Cynthia Lummis for abandoning the crypto industry, citing regulatory capture and opacity as the main reasons.
Royal Challengers Bengaluru IPL Cricket Franchise to Be Acquired by Aditya Birla Group, Times of India, Bolt Ventures and Blackstone for $1.78 Billion
A consortium of investors, led by Aditya Birla and Bolt Ventures, is acquiring Royal Challengers Bengaluru for $1.78 billion, contingent on regulatory approval.